Use of magnetic resonance imaging to support dose selection in a phase II trial of baricitinib combined with conventional synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis

Autor: Peterfy, C, Dicarlo, J, Emery, P, Genovese, MC, Keystone, EC, Taylor, PC, Schlichting, DE, Beattie, SD, Luchi, M, Macias, W

Publikováno v: Journal of Rheumatology. 46(8)

Objective Magnetic resonance imaging (MRI) was used in a Phase IIb study (NCT01185353) of baricitinib in patients with RA to support dose selection for the Phase III program. Methods 301 patients with active RA on stable methotrexate were randomized

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::77f8fb8e523232e26a3943b84d15c640
http://ora.ox.ac.uk/objects/uuid:

Effects of baricitinib on lipid, apolipoprotein, and lipoprotein particle profiles in a phase 2b study in patients with active rheumatoid arthritis

Autor: Kremer, J, Genovese, MC, Keystone, E, Taylor, P, Zuckerman, SH, Ruotolo, G, Schlichting, DE, Crotzer, VL, Nantz, E, Beattie, SD, Macias, WL

Objective: To assess the effects of baricitinib on lipid profile in patients with moderate-to-severe rheumatoid arthritis. Methods: Once-daily baricitinib (1, 2, 4, or 8-mg) or placebo was studied in 301 randomized patients. Changes in lipid profile,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::492d95ea4fb0cd492c14e66201c7312e
https://ora.ox.ac.uk/objects/uuid:9b4a686d-7b65-4a06-8d0c-240b0c107946

Increases in Serum Cholesterol with Baricitinib Treatment are Associated with Favorable Changes in Apolipoprotein Content and with Improvement in DAS28-CRP in Patients with Rheumatoid Arthritis

Autor: Kremer, JM, Genovese, MC, Keystone, E, Taylor, P, Zuckerman, SH, Schlichting, D, Nantz, E, Beattie, S, Macias, W, Holzkämper, T

Publikováno v: 43. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 29. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 25. wissenschaftliche Jahrestagung der Gesellschaft für Kinder-und Jugendrheumatologie (GKJR); 20150902-20150905; Bremen; DOCRA.23 /20150901/

Introduction: Treatment with baricitinib, an oral JAK1/JAK2 inhibitor, demonstrated improvements in signs and symptoms of RA through 52 wks in a Phase 2b study [1] and also in dose- and time-dependent changes in serum lipids, LDL particle size, and H

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef68f114925f94bde112a58756ff64fd

Phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to DMARDs

Autor: Fleischmann, R, Cutolo, Maurizio, Genovese, Mc, Lee, Eb, Kanik, Ks, Sadis, S, Connell, Ca, Gruben, D, Krishnaswami, S, Wallenstein, G, Wilkinson, Be, Zwillich, S. H.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3710::779a0483ae1350e168ea2bab9b1ac8e3
https://hdl.handle.net/11567/298405

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.